Table 3.

Eicosanoids values at baseline and following aspirin challenge in AIA and ATA patients. Results of eicosanoids were recalculated as picograms per milliliter (pg/mL).

	AIA (n = 21)		ATA (n = 23)		P (ANOVA)
	Baseline	After the challenge	Baseline	After the challenge	After the challenge
PGD2	1.49 ± 1.17	1.54 ± 1.02	2.35 ± 2.06	1.80 ± 1.22	0.35
(pg/mL)	1.01	1.21	1.64	1.53
GC/MS	(0.82 ÷ 1,68)	(0.79 ÷ 2.11)	(1.09 ÷ 2.70)	(0.85 ÷ 3.20)
PGD2	1.53 ± 0.81	1.14 ± 0.58	1.76 ± 1.14	1.63 ± 0.93	0.05
(pg/mL)	1.39	1.09	1.48	1.45
HPLC	(0.93 ÷ 2.02)	(0.67 ÷ 1.36)	(0.99 ÷ 2.19)	(0.80 ÷ 2.07)
9α11βPGF2	0.48 ± 0.33	0.50 ± 0.34	0.32 ± 0.18	0.31 ± 0.17	0.59
(pg/mL)	0.36	0.34	0.29	0.28
GC/MS	(0.16 ÷ 0.69)	(0.25 ÷ 0.75)	(0.20 ÷ 0.35)	(0.21 ÷ 0.38)
PGF2α	0.42 ± 0.34	0.40 ± 0.35	0.43 ± 0.33	0.39 ± 0.45	0.82
(pg/mL)	0.28	0.27	0.30	0.23
GC/MS	(0.19 ÷ 0.56)	(0.15 ÷ 0.59)	(0.23 ÷ 0.44)	(0.16 ÷ 0.35)
6-keto-PGF1α	8.94 ± 4.30	8.70 ± 3.72	9.95 ± 4.54	9.55 ± 4.19	0.53
(pg/mL)	7.17	7.22	7.48	7.46
GC/MS	(6.75 ÷ 7.79)	(7.02 ÷ 7.62)	(7.24 ÷ 15.02)	(7.24 ÷ 11.49)
6-keto-PGF1α	8.99 ± 4.41	8.59 ± 3.93	9.69 ± 4.37	9.46 ± 3.95	0.60
(pg/mL)	7.26	6.96	7.40	7.65
HPLC/MS/MS	(6.32 ÷ 8.41)	(6.59 ÷ 8.54)	(7.08 ÷ 13.54)	(7.13 ÷ 10.27)
11-dehydro TXB2	5.74 ± 0.87*	5.94 ± 0.89	6.52 ± 0.92*	6.39 ± 0.94	0.18
(pg/mL)	5.74	6.17	6.81	6.62
GC/MS	(5.14 ÷ 6.34)	(5.16 ÷ 6.49)	(6.35 ÷ 7.00)	(5.70 ÷ 7.16)
11-dehydro TXB2	5.51 ± 0.90*	5.96 ± 1.11	6.40 ± 1.17*	6.18 ± 1.01	0.03*
(pg/mL)	5.49	6.03	6.63	6.18
HPLC/MS/MS	(4.77 ÷ 6.16)	(5.24 ÷ 6.55)	(6.01 ÷ 7.03)	(5.55 ÷ 7.09)
LTC4	4.17 ± 4.56	3.69 ± 7.01	4.35 ± 4.57	1.87 ± 1.73*	0.01*
(pg/mL)	2.30	2.02	2.46	1.06
HPLC/MS/MS	(1.23 ÷ 6.42)	(1.13 ÷ 3.36)	(1.05 ÷ 6.18)	(0.59 ÷ 2.74)
LTD4	0.88 ± 0.60	0.85 ± 0.59	1.58 ± 1.28	1.18 ± 0.88	0.16
(pg/mL)	0.69	0.65	1.34	0.95
HPLC/MS/MS	(0.43 ÷ 1.19)	(0.50 ÷ 1.03)	(0.55 ÷ 2.04)	(0.41 ÷ 1.77)
LTE4	2.03 ± 0.92	3.20 ± 3.63*	2.46 ± 1.43	2.78 ± 1.44*	0.04*
(pg/mL)	1.83	2.33	1.93	2.45
HPLC/MS/MS	(1.28 ÷ 2.71)	(1.57 ÷ 3.44)	(1.30 ÷ 3.45)	(1.54 ÷ 3.69)
Total cysLTs	7.30 ± 4.98	8.02 ± 10.75	8.39 ± 5.62	5.83 ± 3.40	0.24
(pg/mL)	5.97	6.01	7.24	4.90
HPLC/MS/MS	(4.14 ÷ 9.66)	(3.91 ÷ 6.75)	(3.06 ÷ 12.75)	(2.87 ÷ 8.87)
LTB4	69.09 ± 102.42	26.15 ± 25.60*	54.23 ± 99.10	34.81 ± 37.83	0.02*
(pg/mL)	29.66	16.99	27.73	15.35
HPLC/MS/MS	(10.26 ÷ 50.00)	(10.41 ÷ 30.38)	(6.40 ÷ 57.18)	(6.37 ÷ 53.27)
5 HETE	7.15 ± 9.80	3.60 ± 2.69	2.75 ± 1.94	2.61 ± 2.99	0.79
(pg/mL)	2.94	3.41	2.29	1.67
HPLC/MS/MS	(1.96 ÷ 7.41)	(1.67 ÷ 5.29)	(1.43 ÷ 3.12)	(0.78 ÷ 3.00)
12 HETE	6.64 ± 6.16	5.85 ± 10.45	4.03 ± 2.68	3.45 ± 6.75*	0.02*
(pg/mL)	4.05	2.82	3.10	1.93
HPLC/MS/MS	(2.91 ÷ 7.76)	(1.52 ÷ 4.22)	(1.53 ÷ 5.84)	(1.25 ÷ 2.85)
15 HETE	6.99 ± 4.87*	5.81 ± 5.14	3.48 ± 2.78*	5.29 ± 11.76	0.30
(pg/mL)	5.96	4.77	2.95	2.39
HPLC/MS/MS	(4.04 ÷ 8.27)	(2.53 ÷ 6.52)	(1.75 ÷ 3.98)	(1.92 ÷ 2.97)
EXC4	1.05 ± 0.82	0.92 ± 0.89	0.89 ± 0.57	0.83 ± 0.73	0.74
(pg/mL)	0.79	0.59	0.80	0.61
HPLC/MS/MS	(0.45 ÷ 1.61)	(1.18 ÷ 0.58)	(0.36 ÷ 1.40)	(0.25 ÷ 1.07)
EXD4	1.71 ± 2.29	1.78 ± 2.82	1.70 ± 1.76	1.29 ± 1.54	0.909
(pg/mL)	0.73	0.62	1.06	0.74
HPLC/MS/MS	(0.30 ÷ 1.51)	(0.24 ÷ 1.93)	(0.27 ÷ 2.31)	(0.39 ÷ 1.96)
EXE4	5.47 ± 8.61	3.68 ± 6.01	4.01 ± 4.97	2.58 ± 2.63	0.07
(pg/mL)	2.15	1.05	1.59	1.35
HPLC/MS/MS	(0.97 ÷ 4.60)	(0.71 ÷ 2.66)	(0.89 ÷ 5.66)	(0.72 ÷ 3.89)
8-iso-PGF2α	0.25 ± 0.12*	0.28 ± 0.21	0.33 ± 0.15*	0.32 ± 0.10	0.92
(pg/mL)	0.20	0.21	0.35	0.34
GC/MS	(0.17 ÷ 0.28)	(0.19 ÷ 0.26)	(0.20 ÷ 0.42)	(0.25 ÷ 0.39)

Median (25% and 75% percentiles).

AIA: aspirin-induced asthma. ATA: aspirin-tolerant asthma.

*P-values < 0.05; AIA versus ATA at baseline or after the challenge.

P-values:

* AIA versus ATA at baseline.

*baseline versus challenge in AIA.

*baseline versus challenge in ATA.